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When Evidence and Practice Diverge—
Should Nondiabetic Patients With 3-Vessel Disease and
Stable Ischemic Heart Disease Be Preferentially Treated With CABG?
Three sections with opinions separately and independently expressed by:
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American College of CardiologyT he planning of revascularization strategy formultivessel coronary artery disease (CAD)in nondiabetic patients is optimally made
through considering the goals of improving survival
and/or relieving symptoms. Existing clinical practice
guidelines and appropriate use criteria (1–3) state
that in nondiabetic patients with multivessel CAD
and stable ischemic heart disease (SIHD), either coro-
nary artery bypass grafting (CABG) or percutaneous
coronary intervention (PCI) with drug-eluting stents
may be used for those with low SYNTAX (Synergy Be-
tween PCI With Taxus and Cardiac Surgery) scores,
but CABG is preferred for those with intermediate or
high SYNTAX scores. In the overall SYNTAX popula-
tion (4–6), the rates of death and stroke were similar,
but the risk of myocardial infarction (MI) and repeat
revascularization were higher in PCI-treated patients.
At 5-year follow-up, the rates of death/stroke/MI are
8.0% lower, and the rate of repeat revascularization
is 12.8% lower in CABG-treated patients. In the low
SYNTAX score tertile, these trends are not signiﬁ-
cantly different, but they are in the intermediate
and high SYNTAX score subsets. When considering
only survival in the 3 tertiles, there was a 0.9%,
6.7%, and 9.0% difference over 5 years, an average
of 0.2% to 1.8% per year. Yet, PCI is more oftenFrom the *Department of Cardiology, Christiana Care Health System, Ne
Durham, North Carolina; zEmory University School of Medicine, Atlanta, Geor
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guidelines and clinical evidence. Can this apparent
divergence from the evidence base be supported?
Drs. Weintraub and Tcheng and colleagues were
asked to defend or critique the current guidelines.
GUIDELINE PROPONENTS
Pranav Kansara, MD, MS, Sandra Weiss, MD, and
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EVIDENCE FROM THE SYNTAX TRIAL. The SYNTAX
trial provides the only multicenter, randomized
comparison between CABG and drug-eluting stents
among nondiabetic patients with left main artery (LM)
and/or 3-vessel CAD (3VD) (4). The trial randomized
1,800 patients with 3VD or LM disease to undergo
either PCI (n ¼ 903) or CABG (n ¼ 897), with a mean
age of 65 years in both groups. Approximately 75% of
patients did not have diabetes. The rate of patients at
high surgical risk (EuroSCORE [European System for
Cardiac Operative Risk Evaluation] $6) was w20% in
both groups. Almost 60% of the patients had 3VD
(n ¼ 1,095), and 39% of the patients in both groups had
LM disease in addition to other vessel involvement.
The primary endpoint of major adverse cardiac or
cerebrovascular events (MACCE) (composite of deathwark, Delaware; yDuke University Health System,
gia; and the xRush Medical College, Chicago, Illinois.
ontents of this paper to disclose.
15, accepted July 30, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ASCERT = American College of
Cardiology Foundation and the
Society of Thoracic Surgeons
Collaboration on the
Comparative Effectiveness of
Revascularization Strategies
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CEA = cost-effectiveness
analysis
CI = conﬁdence interval
EES = everolimus-eluting
stent(s)
HR = hazard ratio
ICER = incremental cost-
effectiveness ratio
LM = left main artery
MACCE = major adverse
cardiac or cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
QALY = quality-adjusted life
year
RCT = randomized, controlled
trial
RR = risk ratio
SIHD = stable ischemic heart
disease
SoS = The Stent or Surgery
Trial
SYNTAX = Synergy Between
PCI With Taxus and Cardiac
Surgery
3VD = 3-vessel coronary artery
disease
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1648from any cause, MI, stroke, or repeat revas-
cularization) and its components was com-
pared with that in the CABG and PCI groups at
1-, 3-, and 5-year follow-up periods. Both
groups were also compared according to low
(score #22), intermediate (scores of 23 to 32),
and high (scores $33) SYNTAX scores. The
average SYNTAX score was 29.1 in the CABG
group and 28.4 in the PCI group (p ¼ 0.19)
(3). The detailed comparison of clinical end-
points for the CABG group versus the PCI
group for SIHD patients with LM or 3VD dis-
ease at 1-, 3-, and 5-year follow-up periods
(Table 1).
Cl in i ca l outcomes at 1-year . At 1-year, the
CABG group had fewer MACCE compared
with the PCI group (4). This was largely
driven by a decreased rate of repeat revas-
cularization in the CABG group. Death and
MI were comparable in the 2 groups. The
SYNTAX score had signiﬁcant interaction
with the treatment groups (Table 1). MACCE
were not signiﬁcantly different between the
CABG and PCI groups for low and interme-
diate SYNTAX scores. However, MACCE were
lower in patients undergoing CABG with a
high SYNTAX score (Table 1), but the stroke
rate was higher in the CABG cohort.
Cl in i ca l outcomes at 3 years . The 3-year
follow-up again demonstrated fewer MACCE
in the CABG group compared with the PCI
group, driven by a decreased rate of repeat
revascularizations and fewer MIs in the CABG
group compared with the PCI group (5). In
contrast to 1-year follow-up, there was no
longer a signiﬁcant difference in the inci-
dence of stroke between the CABG and PCI
groups at 3 years (Table 1). MACCE werecomparable between the CABG and PCI groups for low
SYNTAX score (Table 1) (6). In LM/3VD patients with
intermediate SYNTAX scores, the CABG group had
fewer MACCE, fewer MIs, and a lower rate of repeat
revascularization. In LM/3VD patients with a high
SYNTAX score, the CABG group had fewer MACCE
compared with the PCI group (Table 1).
Cl in i ca l outcomes at 5 years . Consistent with
1- and 3-year results, CABG remained favorable
compared with PCI for LM/3VD with fewer MACCE
and a lower rate of repeat revascularization (6). Death
of any cause and stroke were not signiﬁcantly
different between the 2 groups (7). MACCE were
comparable between the CABG and PCI groups for low
SYNTAX score and were signiﬁcantly lower in the
CABG group for intermediate and high SYNTAX scorescompared with the PCI group (Table 1) (7). In a sub-
group analysis of patients with 3VD, MACCE were
signiﬁcantly lower in the CABG group compared with
the PCI group (24.2% vs. 37.5%, p < 0.0001) (7). The
3VD subgroup with a low SYNTAX score had compa-
rable MACCE between the CABG and PCI groups
(26.8% vs. 33.3%, p ¼ 0.21). However, the 3VD sub-
group with intermediate and high SYNTAX scores had
lower MACCE with CABG compared with PCI (inter-
mediate SYNTAX score: 25.8% vs. 36.0%, p ¼ 0.008;
high SYNTAX score: 26.8% vs. 44.0%, p < 0.0001) (7).
Cost-effect iveness ana lys i s of the SYNTAX tr ia l .
A cost-effectiveness analysis (CEA) of the SYNTAX
trial was performed for 1- and 5-year outcomes.
Although 1-year survival was comparable between the
CABG and PCI groups, quality-adjusted life years
(QALYs) were lower in the CABG group compared
with the PCI group (0.80 vs. 0.82, p ¼ 0.003) (7). PCI
remained an economically dominant strategy with
respect to QALYs gained at 1-year due to the lower
cost and higher quality-adjusted survival. Due to the
increased rate of repeat revascularization with PCI,
CABG remained the approach to use to avoid repeat
revascularization. Although the CEA will be limited at
1 year, there was an interaction between the SYNTAX
score and the incremental cost-effectiveness ratio
(ICER) measured in cost per QALY gained. PCI was
found to be a dominant strategy in 3VD patients with
low and intermediate SYNTAX scores. However, the
ICER for 3VD with high SYNTAX scores was favorable
for CABG even at 1 year (Table 1). The cost-
effectiveness of CABG compared with PCI at 5-year
follow-up demonstrated that the in-trial cost
remained $5,619 higher in the CABG group at 5 years
with 0.1 QALY gained compared with PCI (8). Lifetime
estimates suggested 0.412 QALY gained for CABG,
making CABG an economically attractive strategy
with an ICER of $16,537/QALY gained for LM/3VD
patients and $4,905/QALY gained for 3VD patients.
The cost-effectiveness of CABG versus PCI based on
SYNTAX score showed CABG as a favorable strategy
for those with high SYNTAX scores (ICER for CABG:
$8,219/QALY gained) and intermediate SYNTAX
scores (ICER for CABG: $36,790/QALY). For low SYN-
TAX scores, PCI remained a dominant strategy (8).
In summary, the clinical and economic outcomes at
5 years in the SYNTAX trial demonstrated CABG to be
superior compared with PCI in nondiabetic patients
with 3VD and SIHD by reducing MACCE, MI, and
repeat revascularization with an attractive ICER of
$12,329/QALY gained. For patients with a high SYN-
TAX score ($33), CABG lowered all-cause mortality at
5 years and still remained highly cost-effective with
an ICER of $8,219/QALY gained compared with PCI.
TABLE 1 Comparison of the Clinical Endpoints in the CABG Group Compared With the PCI Group for SIHD Patients With LM or 3VD From the SYNTAX Trial (4–8)
Patient Groups Endpoint 1-Year Follow-Up 3-Year Follow-Up 5-Year Follow-Up
Overall study population MACCE 12.4% vs. 17.8%, p ¼ 0.002 20.2% vs. 28.0%, p < 0.001 26.9% vs. 37.3%, p < 0.0001
Death from any cause 3.5% vs. 4.4%, p ¼ 0.37 6.7% vs. 8.6%, p ¼ 0.13 11.4% vs. 13.9%, p ¼ 0.10
MI 3.3% vs. 4.8%, p ¼ 0.11 3.6% vs. 7.1%, p ¼ 0.002 3.8% vs. 9.7%, p < 0.0001
Stroke 2.2% vs. 0.6%, p ¼ 0.003 3.4% vs. 2.0%, p ¼ 0.07 3.7% vs. 2.4%, p ¼ 0.09
Repeat revascularization 5.9% vs. 13.5%, p < 0.001 10.7% vs. 19.7%, p < 0.001 13.7% vs. 25.9%, p < 0.0001
CEA
(ICER/QALY gained)
PCI dominant (in-trial period) — $12,329/QALY gained
(lifetime)
Patients with a low
SYNTAX score*
MACCE 14.7% vs. 13.6%, p ¼ 0.71 22.7% vs. 22.5%, p ¼ 0.98 28.6% vs. 32.1%, p ¼ 0.43
Death from any cause — — 10.1% vs. 8.9%, p ¼ 0.64
MI — — 4.2% vs. 7.8%, p ¼ 0.11
Stroke — — 4.0% vs. 1.8%, p ¼ 0.11
Repeat revascularization — — 16.9% vs. 23.0%, p ¼ 0.056
CEA
(ICER/QALY gained)
PCI dominant (in-trial period) — PCI dominant (life-time)
Patients with an intermediate
SYNTAX score*
MACCE 12.0% vs. 16.7%, p ¼ 0.10 18.9% vs. 27.4%, p ¼ 0.02 25.8% vs. 36.0%, p ¼ 0.008
Death from any cause — — 12.7% vs. 13.8%, p ¼ 0.68
MI — 3.2% vs. 7.6%, p ¼ 0.02 3.6% vs. 11.2%, p ¼ 0.0009
Stroke — — 3.6% vs. 2.0%, p ¼ 0.25
Repeat revascularization — 10.1% vs. 17.4%, p ¼ 0.01 12.7% vs. 24.1%, p ¼ 0.0005
CEA (ICER/QALY gained) PCI dominant (in-trial period) — $36,790/QALY gained (lifetime)
Patients with a high
SYNTAX score*
MACCE 10.9% vs. 23.4%, p < 0.001 19.5% vs. 34.1%, p < 0.001 26.8% vs. 44.0%, p < 0.0001
Death from any cause — — 11.4% vs. 19.2%, p ¼ 0.005
MI — — 3.9% vs. 10.1%, p ¼ 0.004
Stroke — — 3.7% vs. 3.5%, p ¼ 0.80
Repeat revascularization — — 12.1% vs. 30.9%, p < 0.0001
CEA (ICER/QALY gained) $43,486/QALY gained (in-trial) — $8,219/QALY gained (lifetime)
*SYNTAX score: low (#22), intermediate (23 to 32), high ($33).
CABG ¼ coronary artery bypass grafting; CEA ¼ cost-effectiveness analysis; ICER ¼ incremental cost-effectiveness ratio; LM ¼ left main artery; MACCE ¼major adverse cardiac and cerebrovascular events
(composite of death from any cause, MI, stroke, or repeat revascularization); MI ¼myocardial infarction; PCI ¼ percutaneous coronary intervention; QALY ¼ quality-adjusted life years; SIHD ¼ stable ischemic
heart disease; 3VD ¼ 3-vessel disease.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 3 , 2 0 1 5 Kansara et al.
N O V E M B E R 2 0 1 5 : 1 6 4 7 – 5 6 When Evidence and Practice Diverge
1649Ev idence from the reg ist ry data . Results similar
to those of the SYNTAX trial were observed in
ASCERT (American College of Cardiology Foundation
and the Society of Thoracic Surgeons Collaboration on
the Comparative Effectiveness of Revascularization
Strategies), the largest and the most comprehensive
observational study. This was a comparative effec-
tiveness study of CABG versus PCI, analyzing data in
the American College of Cardiology Foundation Na-
tional Cardiovascular Data Registry and the Society of
Thoracic Surgeons Adult Cardiac Surgery Database
linked to claims data from the Centers for Medicare
and Medicaid Services for stable multivessel disease
in patients older than 65 years of age (9). Although
the CABG and PCI groups had signiﬁcant baseline
differences, after adjusting with inverse probability
weighting based on propensity score, the CABG
(n ¼ 86,244) and PCI (n ¼ 103,549) groups were
comparable for all baseline characteristics (mean age,
74 years; 65% without diabetes, 53% with 3VD in both
groups). The follow-up ranged from 1 to 5 years
(median follow-up, in years; 2.67 overall, 2.83 CABGgroup, and 2.53 PCI group). At 1 year, there was no
signiﬁcant difference in the adjusted mortality be-
tween the CABG and PCI groups. At 4-year follow-up,
however, patients undergoing CABG had lower mor-
tality compared with patients undergoing PCI (16.4%
vs. 20.8%; risk ratio [RR]: 0.79; 95% conﬁdence in-
terval [CI]: 0.76 to 0.82). This survival difference
persisted across a wide range of subgroup analyses
including the presence or absence of diabetes and
high or low surgical risk groups. The adjusted relative
risk for patients with 3VD and no diabetes undergoing
CABG was 0.81 (95% CI: 0.78 to 0.85).
At 4 years, the CABG group had a signiﬁcantly lower
adjusted incidence of MI compared with the PCI group
(3.2% vs. 6.6%, RR: 0.49; 95% CI: 0.45 to 0.53) (10).
Similarly, at 4 years, the CABG group had a signiﬁ-
cantly lower adjusted composite of death, MI, or
stroke compared with the PCI group (21.6% vs. 26.7%,
RR: 0.81; 95% CI: 0.78 to 0.83). In contrast to 5-year
results from the SYNTAX trial, ASCERT showed that
the CABG group continued to have a signiﬁcantly
higher stroke rate at 4 years compared with PCI
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1650(4.5% vs. 3.1%, RR: 1.43; 95% CI: 1.31 to 1.54). In the
ASCERT, the incidence of stroke in both groups
remained parallel after the initial periprocedural
period. Two randomized clinical trials evaluating
cognitive function at 1 and 5 years demonstrated no
difference in the neuropsychological outcomes be-
tween patients undergoing CABG or PCI (11,12). Also, a
systematic review of 23 randomized clinical trials
showed a higher rate of procedure-related strokes in
patients undergoing CABG comparedwith PCI (13). The
reason for the difference in the adjusted stroke risk at 4
years between the CABG and PCI groups in the ASCERT
compared with the convergence of risk in the ran-
domized trials during long-term follow is unknown.
Being an observational study, the ASCERT has the
important limitation of potential residual treatment
selection bias, even after adjusting the CABG and PCI
groups for signiﬁcant baseline differences. The
probability of a patient being selected for either
CABG or PCI, based on clinical and hospital charac-
teristics and after adjusting for signiﬁcant between-
group differences, was estimated by the propensity
score (9). The performance of a propensity model was
veriﬁed by comparing the distribution of propensity
scores and covariates. It showed that patients un-
dergoing PCI had a lower probability of being
selected for CABG compared with patients undergo-
ing CABG. Although there was an excellent balance
between the CABG and PCI groups, after adjustment
with the use of propensity score–derived inverse
probability weighting, there remains a possibility of
unmeasured confounders such as complexity of cor-
onary disease, chronic total occlusions, and patient
frailty.
CEA of ASCERT. The CEA of ASCERT was recently
reported (14). It demonstrated that the adjusted cost
of CABG was higher for the index hospitalization,
4-year follow-up, and for lifetime. The quality-
adjusted survival was calculated based on published
data on health utilities and adjusted survival. Pa-
tients undergoing CABG gained an average survival of
0.25 years for the 4-year observational study period
and 0.38 years over the lifetime compared with pa-
tients undergoing PCI. The lifetime ICER for CABG
over PCI was $30,454/QALY gained for overall study
population, $36,298/QALY gained for patients with
no diabetes, and $27,080/QALY gained for patients
with 3VD (well below the conventional threshold of
$50,000/QALY gained).
Ev idence from the meta-ana lys i s . A meta-
analysis of 10 randomized trials (N ¼ 7,812, PCI
performed with balloon angioplasty in 6 trials and
with bare metal stents in 4 trials (drug-eluting
stents were not used in these trials) compared theclinical effectiveness of CABG with that of PCI on
long-term mortality in the management of stable
multivessel disease with a median follow-up of 5.9
years. The results showed a trend for decreased
mortality with CABG compared with PCI for multi-
vessel disease (overall: hazard ratio [HR]: 0.91, 95%
CI: 0.82 to 1.02, p ¼ 0.12; nondiabetic patients: HR:
0.98, 95% CI: 0.86 to 1.12, p ¼ 0.014) (15). The study
population included 84% of patients with no dia-
betes, 34% 65 years of age or older, and 37% with
3VD. There was a signiﬁcant interaction between
patient age ($65 years) and the treatment effect on
mortality. CABG improved survival in patients 65
years of age and older compared with PCI (HR: 0.82,
95% CI: 0.70 to 0.97) but did not have any impact
on mortality for patients younger than 65. CABG
improved the composite of 5-year event rate (death,
myocardial infarction, or repeat revascularization)
compared with PCI (20.1% vs. 36.4%, HR: 0.52, 95%
CI: 0.49 to 0.57, p < 0.0001) Another recent meta-
analysis included a total of 6 randomized trials
comparing long-term mortality of CABG versus PCI
for multivessel disease (N ¼ 6,055 patients) with a
median follow-up of 4.1 years (16). In 4 of these 6
trials (n ¼ 3,665: ARTS, MASS II, SoS, SYNTAX), the
majority of the patients were nondiabetic with a
mean age of 60 or older. Here, CABG was noted to
have improved survival compared with PCI (RR:
0.72, 95% CI: 0.58 to 0.89, p ¼ 0.003).
CONCLUSIONS
Oftentimes, the decision to perform PCI as a revas-
cularization strategy is considered ﬁrst when the
stenosis appears to be easily approachable. Howev-
er, the best strategy for long-term outcomes is only
partly dependent on technical considerations. The
available clinical evidence demonstrates a decreased
rate of repeat revascularization and MI with CABG
compared with PCI. CABG improves long-term sur-
vival of patients with a high SYNTAX score. Patients
older than 65 years of age appear to have favorable
long-term outcomes with CABG compared with PCI.
The increased risk of stroke with CABG during the
initial periprocedural period seems to decrease
during long-term follow-up in the randomized
studies, except in the ASCERT. Overall, CABG ap-
pears to be a cost-effective strategy, especially for
patients with intermediate or high SYNTAX scores
compared with PCI. The clinical evidence regarding
mortality and morbidity after CABG or PCI should be
discussed in a “heart team” approach for the
optimal management of SIHD with 3VD in nondia-
betic patients.
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1651COUNTERPOINT: NONDIABETIC PATIENTS
WITH ADVANCED CORONARY DISEASE
SHOULD PREFERENTIALLY BE
CONSIDERED FOR PCI
Matthew C. Hann, MD, and James Tcheng, MD
The current guidelines favoring CABG over PCI,
although based on a large body of evidence, have a
number of inherent limitations, including the
following: 1) the rapid and ongoing evolution of PCI
techniques and technologies, rendering PCI-speciﬁc
outcomes potentially outdated even before being
considered in the creating of guidelines; and 2) the
difﬁculties of applying general guidelines to decision
making at the individual patient level. Regarding the
body of evidence, in an analysis of 2,711 American
College of Cardiology/American Heart Association
guideline recommendations spanning 53 guidelines
across 22 topic areas, recommendations regarding
CABG were found to have only 19% Level of Evidence:
A strength (17). Even then, a number of Level of Evi-
dence: A guidelines are based on data more than 10
years old. Regarding the application of guidelines to
the individual patient, the concept of external validity
(or generalizability) of the trials that provide the basis
for guidelines must be considered (18). Randomized,
controlled trials (RCTs) are designed to assay the
overall standard of treatment of a population of pa-
tients rather than delineate individualized recom-
mendations. In applying guidelines, the clinician
must aggregate and integrate multiple dimensions
(e.g., comorbidities, psychological and social charac-
teristics, operator proﬁciency and competency, health
care setting factors) in addition to determining
whether the speciﬁc guideline in question precisely
ﬁts the clinical context of the treatment decision.
Another issue is the relevance of the component
endpoints comprising clinical trial composite end-
points to the clinical care objectives. The PCI strategy
purposefully relies on limited treatment of only the
coronary segments with the greatest disease. This
targeted strategy anticipates the potential for repeat
intervention given the progressive nature of athero-
sclerosis rather than considering repeat intervention
as an adverse outcome. Given this anticipation,
should repeat revascularization be graded as a failure
of the PCI strategy in clinical trials, while
not counting graft failure as a CABG endpoint equiv-
alent to (or perhaps worse than that of) repeat
revascularization?
A critical drawback is the lack of representation
of symptom relief in the composite endpoints of
clinical trials. The durability of PCI has remarkablyimproved with the evolution of drug-eluting stents.
This salutary beneﬁt is arguably of greater impor-
tance to the patient than a Kaplan-Meier demonstra-
tion of a reduction in mortality. Obviously, PCI is
a much less physically traumatic procedure than
CABG and, where used appropriately, results in
effective and sustained symptomatic relief. More-
over, composite endpoints are heavily biased when a
PCI revascularization procedure is assigned the same
weight as MI and even death in trial endpoint
calculations.
Only in the past 5 years have drug-eluting stent
platforms evolved to the level of commodity. Dra-
matic technology improvements now permit complex
multivessel CAD to be approached via PCI with high
procedural success rates. This has rekindled the
debate of the role of CABG versus PCI in the man-
agement of the patient with advanced coronary artery
disease, particularly when both surgical and percu-
taneous interventions appear to be viable revascu-
larization strategies. A key element is the recognition
that the expression of CAD varies from patient to
patient, from 3 discrete noncalciﬁed lesions that can
be easily treated primarily with PCI to calciﬁed
bifurcation disease and chronic total occlusions that
carry a lower probability of PCI success. Unfortu-
nately, clinical trials have generally not differentiated
anatomy at this level, and even the deﬁnitions of
clinical risk factors (e.g., diabetes and its various
severity levels) vary from trial to trial.
There are no large randomized trials to date of
CABG versus drug-eluting stents limited to patients
without diabetes. The most relevant trial is SYNTAX
(5–7), which randomized both diabetics and non-
diabetic patients to either CABG or PCI with the
paclitaxel-eluting TAXUS stent (Boston Scientiﬁc,
Natick, Massachusetts). To further augment external
validity, SYNTAX was designed as an “all-comers”
trial. To reduce selection bias, consecutive patients
were enrolled. A heart team approach was encour-
aged, and patients were enrolled only if equivalent
anatomic revascularization could be achieved with
CABG or PCI. Patients who were suitable for only 1
treatment option were enrolled in parallel CABG and
PCI registries; those thought to be too high risk for
surgery were offered PCI, and patients with complex
disease not amenable to PCI were offered CABG. The
exclusion of these groups of patients renders current
guideline recommendations valid only in random-
izable patients: although 4,337 patients with multi-
vessel disease were identiﬁed, only 1,800 patients
(41.5%) were randomized; 1,275 (29.4%) were enrolled
in the parallel, nested registries and 1,262 were inel-
igible for various reasons such as treatment
Kansara et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 3 , 2 0 1 5
When Evidence and Practice Diverge N O V E M B E R 2 0 1 5 : 1 6 4 7 – 5 6
1652preference or the declining of informed consent.
Guidelines based on SYNTAX and similar trials are
thus a priori applicable to less than one-half of pa-
tients with multivessel disease.
The results of the SYNTAX trial demonstrated that
at 12 months, all-cause mortality was 4.4% and 3.5%
for PCI and CABG, respectively (p ¼ 0.37). MI occurred
in 4.8% versus 3.3% (p ¼ 0.11), whereas stroke
occurred in 0.6% versus 2.2% (p ¼ 0.003). Evaluating
the composite of all-cause mortality, stroke, or MI,
rates were similar at 7.6% versus 7.7% (p ¼ 0.98). The
rates of symptomatic graft occlusion and stent
thrombosis were also similar at 3.3% versus 3.4% (p ¼
0.89). It was not until the endpoint of repeat revas-
cularization (13.5% for PCI versus 5.9% for CABG, p <
0.001) was included in the primary endpoint of
MACCE (17.8% for PCI vs. 12.4% for CABG, p ¼ 0.002)
that PCI failed to meet the noninferiority margin
speciﬁed as the primary analysis.
A key observation of the SYNTAX trial was the
interaction between the SYNTAX score and outcomes
by revascularization strategy. MACCE rates with PCI
at 12 months increased incrementally with SYNTAX
score; conversely, MACCE rates decreased with CABG.
In patients with a low SYNTAX score (scores: 0 to 22),
the rate of MACCE with PCI was 13.6% versus 14.7%
with CABG (p ¼ 0.71); with a SYNTAX score of 23 to 32,
16.7% with PCI versus 12.0% with CABG (p ¼ 0.10);
and with a high SYNTAX score ($33), 23.4% versus
10.9% (p < 0.001). Importantly, at 5 years, patients
with a low SYNTAX score continued to have similar
MACCE rates with PCI and CABG (32.1% and 28.6%,
respectively, p ¼ 0.43) (20). Patients with an inter-
mediate SYNTAX score had similar rates of the com-
posite of death, stroke, and MI (20.7% vs. 18.0%,
p ¼ 0.42), although MACCE rates (36.0% vs. 25.8%,
p ¼ 0.008) favored CABG due to an increasing needTABLE 2 SYNTAX Trial Outcomes in Nondiabetic Patients (N ¼ 1,348
Clinical Outcome
1-Year
CABG, % PCI, % p Value
Composite MACCE 11.8 15.1 0.08
Death/CVA/MI 6.8 6.8 0.97
All-cause death 2.6 3.0 0.68
Cardiac death 1.6 2.6 0.20
CVA 2.2 0.5 0.006
MI 2.9 4.8 0.08
Graft occlusion/stent thrombosis 3.8 3.4 0.72
Repeat revascularization 5.7 11.1 <0.001
PCI 4.8 9.6 <0.001
CABG 1.1 2.4 0.07
CVA ¼ cerebrovascular accident; other abbreviations as in Table 1.for repeat revascularization in the PCI arm. Thus,
one-third of patients with advanced multivessel cor-
onary disease, speciﬁcally SYNTAX-eligible patients
with a low SYNTAX score, are good candidates for a
PCI ﬁrst approach. An additional one-third of pa-
tients, those with an intermediate score, could be
expected to have similar rates of death, stroke, and
MI while potentially requiring additional revascular-
ization subsequent to the index intervention. Only in
those with a high SYNTAX score is the beneﬁt of a
CABG ﬁrst approach clearly manifest.
Speciﬁc to patients without diabetes in the SYNTAX
trial, analysis of the 1-year data (5) reveals several key
observations (Table 2) (19–21). First, the MACCE rates
for CABG (11.8%) and PCI (15.1%) approximate those of
patients with a low SYNTAX score (14.7% and 13.6%,
respectively). Second, the difference in MACCE rates
between CABG and PCI at 1- and 3-year follow-up is
not statistically signiﬁcant. Critically, the composite
of death, stroke, and MI is no different between the 2
approaches, even at 5 years. Only repeat revasculari-
zation favors the CABG approach, and that difference
is driven predominantly by the need for repeat PCI. At
1 year, 30 patients would need to be treated with
CABG rather than PCI to prevent 1 MACCE, with that
additional event being (most often) a PCI revascular-
ization procedure. The post-procedure hospital stay
was 3.4  4.5 days in the PCI group versus 9.5  8.0
days in the CABG group, clearly favoring PCI, even
without considering postoperative surgical recovery
at home. At longer term follow-up, while the differ-
ences in outcomes (in particularly MACCE, cardiac
death, and repeat revascularization) favoring CABG
did increase, this likely reﬂected progression of the
underlying disease. The reticence to refer patients for
a redo CABG is apparent; no patient underwent redo
CABG over the 5-year period of observation once the) (19–21)
3-Year 5-Year
CABG, % PCI, % p Value CABG, % PCI, % p Value
19.3 24.9 0.014 26.3 34.1 0.002
11.4 13.4 0.293 15.9 19.8 0.069
6.1 6.9 0.519 10.9 12.0 0.48
3.1 5.0 0.087 4.9 7.7 0.035
3.3 1.9 0.096 3.5 2.2 0.15
3.2 7.5 <0.001 3.4 9.9 <0.001
3.4 4.3 0.345 3.9 5.6 0.14
10.0 16.9 <0.001 13.4 22.8 <0.001
9.2 14.3 0.003 12.9 19.3 0.001
1.1 3.9 0.002 1.1 5.8 <0.001
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16531-year anniversary had been achieved. Finally, Table 3
(21) illustrates that the SYNTAX score remains pre-
dictive of long-term outcome, even in patients
without diabetes; as with the overall trial results,
the differential between PCI and CABG widens as
the SYNTAX score increases. When evaluated from the
perspective of patients destined to do well—specif-
ically patients without diabetes and with a low SYN-
TAX score—CABG arguably should be reserved only for
the management of progressive disease once it can no
longer be managed by PCI.
Finally, the incidence of restenosis and the
need for repeat revascularization have substantially
decreased since the SYNTAX experience with the
paclitaxel-eluting stent. The COMPARE (Comparison
of the Everolimus Eluting XIENCE-V Stent with the
Paclitaxel Eluting TAXUS LIBERTE Stent) trial ran-
domized 1,800 patients to PCI with either the
everolimus-eluting stent (EES) or paclitaxel-eluting
stent. At 2 years, the primary endpoint of death,
nonfatal MI, and target vessel revascularization was
9.0% versus 13.7% (p ¼ 0.002) in favor of EES. The
rates of target vessel revascularization were also
lower at 3.2% versus 8.0% (p < 0.001) (22). It could be
hypothesized that, were the SYNTAX trial repeated
today using an EES, the pre-speciﬁed noninferiority
margin in SYNTAX trial would have been met. In 1
analysis, a subgroup of patients in the COMPARE trial
who underwent PCI for multivessel and/or LM dis-
ease (N ¼ 466, with 234 treated with paclitaxel-
eluting stents and 232 with EES) were studied (23).
The results were then stratiﬁed by complexity ac-
cording to the SYNTAX score and suggest that pa-
tients with low SYNTAX scores may have lower
MACCE rates with PCI using EES than with CABG
(18.0% vs. 24.7% projected). In patients with inter-
mediate scores, MACCE rates with PCI using EES and
CABG would still favor PCI (18.6% vs. 22.1% pro-
jected). It is not until the SYNTAX score is high that
CABG becomes superior (36.4% vs. 22.4% projected).
ASCERT (9) demonstrated that at 4 years, in Medi-
care patients with multivessel disease who did not
require emergency treatment, mortality was 16.4% forTABLE 3 SYNTAX Trial Outcomes at 5 Years in Nondiabetic Patients
Clinical Outcome
SYNTAX Score 0–22
CABG, % PCI, % p Value CABG, %
Composite MACCE 27.1 28.7 0.75 24.8
Death/CVA/ MI 13.4 15.0 0.68 16.8
Revascularization 16.4 17.8 0.62 12.4
Abbreviations as in Tables 1 and 2.patients who underwent CABG versus 20.8% for pa-
tients who underwent PCI. However, as would be ex-
pected, the baseline patient characteristics were quite
different, necessitating the use of propensity scores
and inverse-probability weighting to statistically
compensate for these differences and for missing data.
Importantly, the differences that could be addressed
were largely in the realm of clinical risk factors and
other clinical characteristics; the only anatomic data
were the number of diseased coronary arteries and the
presence of proximal left anterior descending disease.
Although exceedingly well conducted, this observa-
tional study remains largely in the realm of hypothesis
generation, particularly given the lack of in-depth
knowledge about the other dimensions of non-
captured information that contribute to the decision
of PCI versus CABG in multivessel disease.
In conclusion, many patients with multivessel CAD
can be appropriately managed with a PCI-ﬁrst strat-
egy. Seemingly applicable clinical trials to address the
revascularization strategy question (and the guide-
lines derived thereof) have limited external validity
and do not reﬂect the latest in interventional tech-
nologies. Careful case selection and consideration of
technical details are crucial in choosing the right
strategy for the right patient.
SUMMARY AND CONCLUSIONS
Lloyd W. Klein, MD
This discussion highlights an important clinical
dilemma: in developing a revascularization strategy,
there is a signiﬁcant divergence in clinical prac-
tice from the existing guidelines. Results from the
SYNTAX trial would suggest that only the least com-
plex one-third of patients with 3VD might be candi-
dates for PCI and that CABG should be preferentially
considered for the majority. However, actual practice
suggests that PCI is more often selected. This is
conﬁrmed in ASCERT (9), in which the Medicare PCI
population in institutions that collected data for both
National Cardiovascular Data Registry and Society ofby SYNTAX Score (N ¼ 1,348) (21)
SYNTAX Score 23–33 SYNTAX Score $33
PCI, % p Value CABG, % PCI, % p Value
34.2 0.037 27.2 39.6 0.004
20.2 0.38 17.5 24.4 0.065
23.2 0.004 11.9 27.4 <0.001
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1654Thoracic Surgeons registries was almost twice as large
as the CABG population.
This apparent discrepancy is connected to the
recognition that patients who are enrolled in RCTs are
a select subgroup of those who are seen in practice.
Often, patients seen in actual practice do not meet a
relevant study’s inclusion or exclusion criteria, and,
hence, it is ambiguous whether the trial results
pertain to them because the beneﬁts of any treatment
option are usually not homogeneous, are useful for
some subgroups, and negligible (or even harmful) for
others.
In particular, frailty and severe comorbid conditions
are not evaluated in RCTs or captured in registries, but
are always taken into account in clinical practice.
Patients who are selected for PCI in clinical practice
are frequently dissimilar to those who have CABG.
For example, ASCERT showed that Medicare patients
with multivessel CAD undergoing revascularization
do not have the same propensity to undergo the 2
procedures: The propensity distribution curve shows
a bimodal distribution with little overlap at a nadir
between 0.4 and 0.6.
Why does CABG outperform PCI in RCTs? There are
3 main factors: 1) The high patency rate of the left
internal mammary artery graft; 2) stents treat only the
segment in which they are placed, but a graft bypasses
all proximal segments, including vulnerable plaque
that has not produced a signiﬁcant luminal narrowing;
and 3) complete revascularization is more commonly
achieved with CABG. The latter reason is especially of
interest: in SYNTAX, almost 5 stents per patient were
placed, for a total length of w9 cm, with incomplete
revascularization in 43.3%. In the CABG group, w3
grafts/patient were placed, with an incomplete
revascularization rate of 36.8%. This signiﬁcant dif-
ference was associated with increased adverse events
(24). Such a critical factor in making individual de-
cisions must be accounted for in evaluating medical
judgments, and the “residual SYNTAX score” may be
of enormous value in shared decision making. It has
been estimated, using a residual score of #8 as crite-
rion, that 71% of SYNTAX patients are best treated
with CABG, whereas for the remainder, PCI is a
reasonable alternative (6). In patients in whom a
complete, or similar degree of incomplete, revascu-
larization is anticipated with both techniques, there is
insufﬁcient analysis to conclude whether there may
be equivalent outcomes in some subgroups.
Moreover, the absolute survival differences are
small enough that a sensible physician can reasonably
advise, or a patient intelligently desire, multivessel
stenting or optimal medical therapy, in some cases.
An approximate 1% per year survival advantage isnot so overwhelming as to exclude additional appo-
site considerations. In particular, the relatively higher
30-day mortality in CABG in patients with signiﬁcant
left ventricular dysfunction might rationally affect
decision making in some patients even when longer
term outcomes favor CABG (25). In both SYNTAX and
ASCERT, there was no difference in survival at 1 year
overall, a ﬁnding that emphasizes that the longer
term beneﬁts of CABG can only be enjoyed if the pa-
tient survives the operation. Moreover, the relative
differences in the rate of periprocedural MI after
CABG or PCI may well be ascribed to differences in
deﬁnition or reporting standards and includes many
silent troponin leaks after MI of questionable signiﬁ-
cance in the PCI group.
Patients who are turned down for CABG represent a
complex subgroup. When surgery is declined, PCI
becomes the alternative for these patients who pose
the highest risk; yet registries and RCTs do not cap-
ture this measure. In such cases, surgeons “preserve”
their mortality statistics, but interventionists are not
afforded this luxury.
Patient preference is especially worthy of consid-
eration. The expected beneﬁt associated with a
particular therapy varies widely from patient to pa-
tient. The evidence base is not sufﬁciently granular to
make this assessment for every patient and ideally
should be individualized. Additionally, there are
endpoints important to physicians and patients that
are not studied in RCTs but that may be more impor-
tant, and occasionally even imperative, than death/
MI/stroke. Quality of life, relief from angina, recuper-
ation time, and concern for permanent neurological
damage are not easy to objectify and are not typically
the endpoints of RCTs, but undeniably are important
to consider. In particular, elderly patients frequently
prefer treatments that tend to preserve quality rather
than quantity of life. Physicians also tend to downplay
complications of procedures that are not catastrophic;
for example, the incidence of postoperative atrial
ﬁbrillation, pericarditis, and infection might reason-
ably be considered in treatment choice; conversely,
post-PCI procedural bleeding and the need for more
frequent follow-up and additional procedures might
alter another patient’s inclination. Such trade-offs are
not simple but require the patient to thoughtfully
consider the expected beneﬁts and the risks before
making a decision. They need to be able to choose their
own priorities and values and should not be compelled
by a “one-size-ﬁts-all” inference: repeat procedures,
for example, may be an acceptable downside for many.
An innovative approach to making the best deci-
sion for each patient is to consider the concept of
value, which is deﬁned as quality achieved per dollar
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1655spent. By evaluating each treatment modality by both
its provision of results as well as its cost, a reasoned
approach is ensured. A promising tactic (26) is to
combine value with appropriateness. By including
clinically deﬁned outcomes, patient-expected out-
comes, and relative cost in the equation, the “real
value” of a procedure to that patient might be
objectively appraised.
One signiﬁcant obstacle to the value proposition is
that cost, the denominator, tends to overwhelm
consideration of the clinical beneﬁt (27). Cost is a
critical component from the societal perspective, but it
is not the patient’s concern: he or she seeks the best
advice for his or her situation. What advice do we give
if the most effective treatment is also the most costly?
What weight should cost receive relative to outcomes?
Howmuch improved effectiveness is worth howmuch
incremental cost? Is differential value based only on
cost ethical? Several analyses have shown that along
with the beneﬁts of CABG comes a substantially higher
cost (8,14). Moreover, these analyses fail to consider
that when the PCI strategy is selected, usually repeat
procedures are not required, and then it is signiﬁcantly
less expensive than CABG. In other cases, multiple PCI
procedures or cases with greater equipment use (i.e.,
mechanical circulatory support such as intra-aortic
balloon pump and left ventricular support devices)
can be quite expensive: should PCI be denied solely
because of increased cost?
The controversy highlighted in this discussion is a
direct consequence of how guidelines are developedand interpreted. Guideline committees develop rec-
ommendations based on the evidence derived from
the “uncomplicated” case. However, their conclusions
are applied to patients beyond those who would have
been potential enrollees in RCTs. Moreover, the eco-
nomic and social consequences of using these guide-
lines and appropriate use criteria as reasons to deny
payment for a judiciously selected alternate strategy
are troubling and scientiﬁcally completely unjustiﬁ-
able. For these reasons, future panels should avoid
making strong recommendations when the best
treatment strategy heavily depends on the patient’s
context, goals, values, and preferences and should be
reserved for evidence that demonstrates that 1 treat-
ment option is deﬁnitely superior. When the evidence
is conditional or less deﬁnitive, panels should indicate
so and produce a provisional recommendation. These
should explicitly describe how patient preferences and
perspective may affect the choice between the rele-
vant options (28). Although it is probably impossible to
construct a decision tree that covers every conceivable
situation, future iterations of the guidelines and
appropriate use criteria must do a better job of simu-
lating the decision-making process, deﬁning elements
that appropriately inﬂuence the application of the
recommendation, and acknowledging “gray zones.”
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Lloyd W. Klein, Rush Medical College, 3000 North
Halsted Avenue, Suite #625, Chicago, Illinois 60614.
E-mail: lloydklein@comcast.net.RE F E RENCE S1. Levine GN, Bates ER, Blankenship JC, et al.
2011 ACCF/AHA/SCAI guideline for percutaneous
coronary intervention: a report of the Amer-
ican College of Cardiology Foundation/American
Heart Association Task Force on Practice Guide-
lines and the Society for Cardiovascular Angiog-
raphy and Interventions. J Am Coll Cardiol 2011;
58:e44–122.
2. Fihn SD, Gardin JM, Abrams J, et al. 2012
ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS guide-
line for the diagnosis and management of pa-
tients with stable ischemic heart disease: a
report of the American College of Cardiology
Foundation/American Heart Association Task
Force on Practice Guidelines, and the American
College of Physicians, American Association for
Thoracic Surgery, Preventive Cardiovascular
Nurses Association, Society for Cardiovascular
Angiography and Interventions, and Society of
Thoracic Surgeons. J Am Coll Cardiol 2012;60:
e44–164.
3. ACCF/SCAI/STS/AATS/AHA/ASNC 2012 appro-
priateness criteria for coronary revascularization
focused update. J Am Coll Cardiol 2012;59:
857–81.4. Serruys PW, Morice MC, Kappetein AP, et al.
Percutaneous Coronary Intervention Versus
Coronary-Artery Bypass Grafting for Severe Coro-
nary Artery Disease. N Engl J Med 2009;360:
961–72.
5. Kappetein AP, Feldman TE, Mack MJ, et al.
Comparison of coronary bypass surgery with
drug-eluting stenting for the treatment of left
main and/or three-vessel disease: 3-year follow-
up of the SYNTAX trial. Eur Heart J 2011;32:
2125–34.
6. Mohr FW, Morice M-C, Kappetein AP, et al.
Coronary artery bypass graft surgery versus
percutaneous coronary intervention in patients
with three-vessel disease and left main coronary
disease: 5-year follow-up of the randomised,
clinical SYNTAX trial. Lancet 2013;381:629–38.
7. Cohen DJ, Lavelle TA, Van Hout B, et al. Eco-
nomic outcomes of percutaneous coronary inter-
vention with drug-eluting stents versus bypass
surgery for patients with left main or three-vessel
coronary artery disease: one-year results from the
SYNTAX trial. Catheter Cardiovasc Interv 2012;79:
198–209.8. Cohen DJ, Osnabrugge RL, Magnuson EA,
et al. Cost-effectiveness of percutaneous co-
ronary intervention with drug-eluting stents
versus bypass surgery for patients with 3-vessel
or left main coronary artery disease: ﬁnal results
from the Synergy Between Percutaneous Co-
ronary Intervention With TAXUS and Cardiac
Surgery (SYNTAX) trial. Circulation 2014;130:
1146–57.
9. Weintraub WS, Grau-Sepulveda MV, Weiss JM,
et al. ASCERT: comparative effectiveness of re-
vascularization strategies. N Engl J Med 2012;366:
1467–76.
10. Edwards FH, Shahian DM, Grau-Sepulveda MV,
et al. Composite outcomes in coronary bypass
surgery versus percutaneous intervention. Ann
Thorac Surg 2014;97:1983–8; discussion 1988–90.
11. Hlatky MA, Bacon C, Boothroyd D, et al.
Cognitive function 5 years after randomization to
coronary angioplasty or coronary artery bypass
graft surgery. Circulation 1997;96 9 Suppl:II-11–4.
discussion II-15.
12. Währborg P, Booth JE, Clayton T, et al.
Neuropsychological outcome after percutaneous
Kansara et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 3 , 2 0 1 5
When Evidence and Practice Diverge N O V E M B E R 2 0 1 5 : 1 6 4 7 – 5 6
1656coronary intervention or coronary artery bypass
grafting: results from the Stent or Surgery (SoS)
Trial. Circulation 2004;110:3411–7.
13. Bravata DM, Gienger AL, McDonald KM,
Sundaram V, Perez MV. Systematic review: the
comparative effectiveness of percutaneous. Ann
Intern Med 2007;147:703–16.
14. Zhang Z, Kolm P, Grau-Sepulveda MV, et al.
Cost-effectiveness of revascularization strategies.
J Am Coll Cardiol 2015;65:1–11.
15. Hlatky M, Boothroyd DB, Bravata DM, et al.
Coronary artery bypass surgery compared with
percutaneous coronary interventions for multi-
vessel disease: a collaborative analysis of individual
patient data from ten randomised trials. Lancet
2009;373:1190–7.
16. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C.
Coronary artery bypass grafting vs. percutaneous
coronary intervention and long-term mortality
andmorbidity inmultivessel disease: meta-analysis
of randomized clinical trials of the arterial grafting
and stenting era. JAMA Intern Med 2014;174:
223–30.
17. Tricoci P, Allen JM, Kramer JM, Califf RM,
Smith SC Jr. Scientiﬁc evidence underlying the
ACC/AHA clinical practice guidelines. JAMA 2009;
301:831–41.18. Rothwell PM. External validity of randomized
controlled trials: “To whom do the results of this
trial apply?”. Lancet 2005;365:82–93.
19. Banning AP, Westaby S, Morice MC, et al. Dia-
betic andnondiabetic patientswith leftmain and/or
3-vessel coronary artery disease: comparison of
outcomes with cardiac surgery and paclitaxel-
eluting stents. J Am Coll Cardiol 2010;55:1067–75.
20. Mack MJ, Banning AP, Serruys PW, et al.
Bypass versus drug-eluting stents at three years in
SYNTAX patients with diabetes mellitus or meta-
bolic syndrome. Ann Thorac Surg 2011;92:2140–6.
21. Kappetein AP, Head SJ, Morice MC, et al.,
SYNTAX Investigators. Treatment of complex
coronary artery disease in patients with diabetes:
5-year results comparing outcomes of bypass
surgery and percutaneous coronary intervention in
the SYNTAX trial. Eur J Cardiothorac Surg 2013;43:
1006–13.
22. Smits PC, Kedhi E, Royaards KJ, et al. 2-year
follow-up of a randomized controlled trial of
everolimus- and paclitaxel-eluting stents for cor-
onary revascularization in daily practice. J Am Coll
Cardiol 2011;58:11–8.
23. Smits PC, Vlachojannis GJ, Farooq V, et al.
TCT-587: what if current generation drug-eluting
stents were used in the SYNTAX trial? Analysis ofthe COMPARE and SYNTAX trials 5 year follow-up.
J Am Coll Cardiol 2014;64:B171.
24. Head SJ, Mack MJ, Holmes DR Jr., et al. Inci-
dence, predictors and outcomes of incomplete
revascularization after percutaneous coronary
intervention and coronary artery bypass grafting:
a subgroup analysis of 3-year SYNTAX data. Eur J
Cardiothoracic Surg 2012;41:535–41.
25. Velazquez EJ, Lee KL, Deja MA, et al. Coro-
nary-artery bypass surgery in patients with left
ventricular dysfunction. N Engl J Med 2011;364:
1607–16.
26. Duffy PL. Real value: a strategy for interven-
tional cardiologists to lead healthcare reform.
Cath Cardiovasc Int 2015;84:188–91.
27. Ho PM, O’Donnell CI, Bradley SM, et al. 1-Year
risk-adjusted mortality and costs of percutaneous
coronary intervention in the Veterans Administra-
tion. J Am Coll Cardiol 2015;65:236–42.
28. Montori VM, Brito JP, Murad MH. The optimal
practice of evidence-based medicine. Incorpo-
rating patient preferences in practice guidelines.
JAMA 2013;310:2503–4.KEY WORDS CABG, cost effectiveness, PCI,
quality of life, stent(s)
